secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001104659-24-026225
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax settles Gavi arbitration: pays $75M upfront, $400M deferred through 2028
--------------------------------------------------------------------------------

- Initial cash payment of $75M to Gavi made Feb 20; deferred payments of $80M/yr through 2028 total $400M.
- Deferred payments may be reduced by annual vaccine credits for qualifying sales to low-income countries.
- Gavi receives security interest in accounts receivable from Serum Institute of India under Matrix-M supply agreement.
- Settlement terminates the May 2021 Advanced Purchase Agreement and ends related arbitration proceedings.
- Novavax may price vaccines for qualifying countries in its discretion; credit applied at actual price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924026225/0001104659-24-026225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-026225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer